Description
Doxorubicin is an anthracycline that exhibits anticancer chemotherapeutic and anti-parasitic, antimalarial activities. Doxorubicin is a DNA intercalator that inhibits topoisomerase II and is clinically used to treat various cancers; it is part of the CHOP and ABVD chemotherapy regimens. Doxorubicin also promotes histone H2AX eviction from chromatin, limiting DNA repair mechanisms. Additionally, this compound inhibits growth of Plasmodium.
References
Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908. PMID: 23715267.
Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013 Feb;65(2):157-70. PMID: 23278683.
Gamo FJ, Sanz LM, Vidal J, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010 May 20;465(7296):305-10. PMID: 20485427.
Squillace RM, Miller D, Cookson M, et al. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther. 2011 Oct;10(10):1959-1968. PMID: 21825008.